03 July 2024 : Clinical Research
Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma
Jie Wang1ABCDEFG*, Ming Yang2CD, Sheng Chen2CEF, Hongbo Zhu1AB, Zhirong Zhang1CDDOI: 10.12659/MSM.943551
Med Sci Monit 2024; 30:e943551
Table 1 Basic information of the cohort.
| Characters | Number | Percentage |
|---|---|---|
| Gender | ||
| Male | 54 | 64.29% |
| Female | 30 | 35.71% |
| Age | ||
| ≤60 | 62 | 73.81% |
| >60 | 22 | 26.19% |
| Tumor diameter (cm) | ||
| ≤5 | 32 | 38.10% |
| >5 | 52 | 61.90% |
| Macroscopic type | ||
| Ulcerative | 52 | 61.90% |
| Polypoid | 13 | 15.48% |
| Others | 19 | 22.62% |
| Lesion number | ||
| Single | 68 | 80.95% |
| Multiple | 16 | 19.05% |
| Site | ||
| Stomach | 47 | 55.95% |
| Intestine | 37 | 44.05% |
| Chemotherapy | ||
| No | 40 | 47.62% |
| Yes | 44 | 52.38% |
| Serum LDH | ||
| Normal | 54 | 64.29% |
| High | 30 | 35.71% |
| PS | ||
| <2 | 73 | 86.90% |
| 2–4 | 11 | 13.10% |
| Luanguo stage | ||
| I–II1 | 65 | 77.38% |
| II2–IV | 19 | 22.62% |
| IPI | ||
| <3 | 77 | 91.67% |
| 3–5 | 7 | 8.33% |
| CST1 | ||
| Low | 23 | 27.38% |
| High | 61 | 72.62% |
| LDH – lactate dehydrogenase; PS – performence status; IPI – International Prognostic Index; CST1 – Cystatin SN. | ||